alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 157 studies in Brain scans and imaging of type cross-sectional study (page 1 of 7) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 157 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA neurology 2024-06-01

Although AD cases with a CLix score less than 10 had higher cortical tangle count, we found lower percentage of CD68-activated microglia/macrophage burden (median [IQR], 0.46% [0.32%-0.75%]) compared with cases with a CLix score of 10 to 30 (median [IQR], 0.75% [0.51%-0.98%]) and on par with a CLix score of 30 or greater (median [IQR], 0.40% [0.32%-0.57%]; P = .02). 3 key findings →

Design: cross-sectional Participants: 60 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

✓ Peer-reviewed alzhub usefulness score 68 out of 100. JAMA neurology 2020-08-01

In this study, elevated [18F]RO948 SUVRs were most often seen among Aβ-positive cases, which suggests that [18F]RO948 has high specificity for AD-type tau and highlights its potential as a diagnostic marker in the differential diagnosis of AD. 4 key findings →

Design: cross-sectional Participants: 257 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Neurology 2019-01-09

Our findings suggest that tau PET is more sensitive than Aβ PET and measures of cortical thickness for detecting early cognitive changes in preclinical AD. 2 key findings →

Design: cross-sectional Participants: 106 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Brain : a journal of neurology 2023-09-01

We found that the association between higher baseline tau-PET levels (quantified in a temporal meta-region of interest) and rate of cognitive decline (measured with repeated Mini-Mental State Examination) was adversely modified by older age (Stβinteraction = -0.062, P = 0.032), higher education level (Stβinteraction = -0.072, P = 0.011) and higher intracranial volume (Stβinteraction = -0.07, P = 0.016). 5 key findings →

Design: cross-sectional Participants: 200 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Default mode network connectivity in stable vs progressive mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurology 2011-01-12

GOF indices were highest in normal controls, intermediate in MCI, and lowest in AD (p Conclusions fMRI connectivity indices distinguish patients with MCI who undergo cognitive decline and conversion to AD from those who remain stable over a 2- to 3-year follow-up period. 3 key findings →

Design: cross-sectional Participants: 68 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS)

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Diabetes care 2017-09-15

More-severe diabetes (defined by higher HbA 1c and longer disease duration) but not prediabetes or less-severe diabetes was associated with smaller brain volumes and an increased burden of brain vascular pathology. 3 key findings →

Design: cross-sectional Participants: 1,713 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2022-07-01

In this cross-sectional study, abnormal central vascular hemodynamics were associated with higher tau burden in specific brain regions. 5 key findings →

Design: cross-sectional Participants: 3,171 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. The Lancet. Neurology 2015-11-18

Our transition rates suggest that brain ageing is a nearly inevitable acceleration toward worse biomarker and clinical states. 5 key findings →

Design: cross-sectional Participants: 4,049 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Comorbidity of dementia: a cross-sectional study of primary care older patients

✓ Peer-reviewed alzhub usefulness score 62 out of 100. BMC psychiatry 2014-03-20

The analysis of the comorbidities associated with an index disease (e.g., dementia) must not be exclusively based on prevalence rates, but rather on methodologies that allow the discovery of non-random associations between diseases. 4 key findings →

Design: cross-sectional Participants: 72,815 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Disentangling the effects of Alzheimer's and small vessel disease on white matter fibre tracts

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Brain : a journal of neurology 2023-02-01

Alzheimer's disease and cerebral small vessel disease are the two leading causes of cognitive decline and dementia and coexist in most memory clinic patients. 3 key findings →

Design: cross-sectional Participants: 387 Evidence: low

Full summary, score breakdown and related studies → Original source

A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18F-MK-6240 PET

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2022-09-29

For the visual read, the readers assessed 8 gray-matter regions per hemisphere as negative (no abnormal uptake) or positive (1%-25% of the region involved, 25%-75% involvement, or >75% involvement) and then characterized the tau binding pattern as positive or negative for evidence of tau and, if positive, whether brain uptake was in an AD pattern. 5 key findings →

Design: cross-sectional Participants: 102 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Brain : a journal of neurology 2017-03-01

For amyloid positron emission tomography positive (Aβ+) subjects, flortaucipir neocortical standard uptake value ratio was significantly higher with more advanced clinical stage (Alzheimer's disease > mild cognitive impairment > older cognitively normal) and was significantly elevated for Aβ+ mild cognitive impairment and Alzheimer's disease subjects relative to the respective Aβ- subjects. 5 key findings →

Design: cross-sectional Participants: 217 Evidence: low

Full summary, score breakdown and related studies → Original source

SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline

✓ Peer-reviewed alzhub usefulness score 61 out of 100. PloS one 2022-11-03

Compared to CSF p-tau, meta-temporal, and averaged Braak tau PET ROIs, SPARE-Tau showed the strongest association with baseline ADAS-cog13 scores and diagnosis. 5 key findings →

Design: cross-sectional Participants: 587 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024-05-01

In the cross-sectional study, CLs in both the Aβ- and the Aβ+ groups were impacted by the FWHM of the reconstruction method. 5 key findings →

Design: cross-sectional Participants: 89 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Science translational medicine 2014-03-01

Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD) begins many years before the appearance of cognitive symptoms. 3 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2009-07-01

We found no significant correlation between CSF biomarkers and cognitive scores in any of the 3 clinical groups individually. 2 key findings →

Design: cross-sectional Participants: 399 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events